» Articles » PMID: 17063185

Interferons, Immunity and Cancer Immunoediting

Overview
Journal Nat Rev Immunol
Date 2006 Oct 26
PMID 17063185
Citations 738
Authors
Affiliations
Soon will be listed here.
Abstract

A clear picture of the dynamic relationship between the host immune system and cancer is emerging as the cells and molecules that participate in naturally occurring antitumour immune responses are being identified. The interferons (IFNs) - that is, the type I IFNs (IFNalpha and IFNbeta) and type II IFN (IFNgamma) - have emerged as central coordinators of tumour-immune-system interactions. Indeed, the decade-old finding that IFNgamma has a pivotal role in promoting antitumour responses became the focus for a renewed interest in the largely abandoned concept of cancer immunosurveillance. More recently, type I IFNs have been found to have distinct functions in this process. In this Review, we discuss the roles of the IFNs, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.


Targeting leukocyte immunoglobulin‑like receptor B2 in the tumor microenvironment: A new treatment prospect for solid tumors (Review).

Cao M, Luan J, Zhai C, Liu H, Zhang Z, Guo N Oncol Lett. 2025; 29(4):181.

PMID: 39990807 PMC: 11843431. DOI: 10.3892/ol.2025.14927.


Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.

Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.

PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.


Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.

Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E Biomedicines. 2025; 13(1).

PMID: 39857692 PMC: 11762644. DOI: 10.3390/biomedicines13010108.


The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer.

Santoso A, Levink I, Pihlak R, Chau I Curr Oncol. 2025; 32(1).

PMID: 39851940 PMC: 11763487. DOI: 10.3390/curroncol32010024.